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Abstract: In rhesus monkeys, acute administration of levonantradol and nantradol
produced signs of CNS depression, including ataxia with body sag, pupil dilation,
ptosis, dozing, and reduced responsivity to external stimuli. Neither compound sup-
pressed the morphine withdrawal syndrome; however, both alleviated the chronic
abdominal contraction associated with withdrawal. The directly observable effects of
these compounds were not antagonized by naloxone. When levonantradol was admin-
istered every 6 hours, marked tolerance developed to both the effects of levonantradol
and nabilone and THC. No signs of withdrawal were observed when levonantradol
injections were abruptly discontinued. When substituted in lieu of codeine under an
intravenous drug self-administration procedure, neither levonantradol nor nantradol
maintained responding at rates higher than those maintained by their vehicle. Finally,
the discriminative effects of levonantradol were not equivalent to those of the narcot-
ics ethylketazocine or etorphine.
C ANNABINOIDS have potential therapeu-
tic applications in the treatment of
glaucoma, asthma, nausea and vomiting
associated with cancer chemotherapy, and
pain.’ Widespread recreational use of mari-
huana, however, raises questions about
whether the potential for abuse of novel
cannabinoids may limit their usefulness as
therapeutic agents. At present, there are no
generally accepted protocols for the preclin-
ical evaluation of the abuse liability of can-
nabinoids. In the absence of such protocols,
and in the absence of standards of refer-
ence, the present study evaluated two can-
nabinoids in the rhesus monkey under
procedures useful in evaluating abuse lia-
bility of narcotic analgesics.
The comparison of narcotics and canna-
binoids is of interest, since there are some
similarities in their various actions. For in-
stance, a number of studies2 suggest that
9-tetrahydrocannabinol (THC) has some
analgetic effects in rodents under a variety
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of procedures. Some cannabinoids, al-
though perhaps not THC, may have anal-
gesic actions in humans.6 Additionally,
cannabinoids have been suggested to sup-
press the withdrawal syndrome produced
by morphine deprivation in rodents and
primates.”8
In the present study, levonantradol and
nantradol, two potent cannabinoids with
therapeutic potential,9 were assessed for
capacity to suppress withdrawal signs in
the 14-hour withdrawn morphine-dependent
rhesus monkey. In addition, the grossly ob-
servable effects induced by levonantradol
were studied in normal, nondependent
monkeys and in nondependent monkeys
treated with the narcotic antagonist nalox-
one. The effects of levonantradol were also
evaluated in monkeys trained with etor-
phine or ethylketazocine as discriminative
stimuli.’0” Previous studies’2”3 in rodents
have shown that the discriminative effects
of cannabinoids (e.g., THC) are distinct
from those of a variety of other classes of
CNS-active agents, including narcotics.
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The present study extended those studies to
primates and to a distinct type of narcotic
agonist, ethylketazocine, that has discrim-
inative effects that are different from
those of morphine.” Further, the ability of
nantradol and levonantradol to maintain
responding in rhesus monkeys trained to
self-administer codeine’4 was assessed. A
variety of narcotic agonists with abuse lia-
bility are self-administered by monkeys
under many conditions’5; however, it has
been found generally that THC fails to
maintain more responding than that main-
tained by its vehicle.’’8 Finally, the devel-
opment of tolerance and dependence upon
repeated administration of levonantradol
was assessed. Tolerance to some of the be-
havioral effects of THC and morphine can
be quite pronounced’9’20; however, there is
only a single report2’ of dependence devel-
opment to THC in nonhuman primates.
Methods
Dependence and Tolerance Studies
Suppression of Morphine Withdrawal.
Male and female rhesus monkeys weighing
2 to 5 kg were trained to routinely receive
morphine injections and were maintained
on a regular schedule of injections (3mg/kg
every 6 hours) that produces physiologic
dependence in this species.n The monkeys
were housed in groups of four to six in wire
mesh pens measuring 1.2 m by 1.5 m by 2.1
m; the floor of each pen was covered with
wood shavings. The monkeys were fed ap-
proximately 40 to 100 Gm Purina Monkey
Chow containing 608.3 Gm/ton isoniazid
daily. Drinking water was available at all
times. The colony room was lit from 7 A.M.
to 1 A.M. daily.
The procedures described by Deneau and
Seevers22 and Villarrealu were used to as-
sess the ability of cannabinoids to suppress
the signs of morphine withdrawal. After at
least three months of stabilization on the
above schedule of morphine administra-
tion, injections were periodically withheld,
which was followed by the development of
withdrawal signs. Fourteen hours after the
last morphine injection, when withdrawal
signs are approximately half of the max-
imal severity, the cannabinoids, 3 mg/kg
morphine, or vehicle were tested for their
ability to relieve the withdrawal signs.
Generally, morphine-like agonists sup-
press the withdrawal signs, whereas nar-
cotic antagonists exacerbate those signs.
In contrast to the morphine-like agonists,
drugs identified as kappa agonists neither
suppress nor exacerbate withdrawal signs;
rather, these compounds at suitable doses
produce a constellation of signs of seda-
tion.24 Observations of the monkeys were
made just prior to test injections at the first
two half-hour intervals following the injec-
tion and at subsequent hourly intervals.
When observations were complete and a
withdrawal syndrome was still present, the
monkeys were given 8.0 mg/kg morphine to
terminate withdrawal. Three to four mon-
keys were studied at each dose. At each ob-
servation period, the maximum with-
drawal or grade of sedation displayed by
each monkey was determined by a trained
observer who knew only a coded number
and dose of the test compound the subject
had received.
Acute and Chronic Effects of Levonan-
tradol in Normal Monkeys. Male and fe-
male rhesus monkeys weighing 4 to 6 kg
were trained to routinely receive injections
and were housed, fed, and watered in a
manner similar to that of the morphine-
dependent monkeys.
Following periodic injections of levonan-
tradol, subjects were graded for direct ef-
fects according to a scale based on observa-
tions of effects of a variety of cannabinoids.
Each subject was assigned a score of either
0, 1, or 2 for a particular effect depending on
whether it was absent, present, or present
and marked, respectively. The effects were
pupil dilation, ptosis, ataxia and body sag,
dozing, and a decrease in responsiveness to
external stimuli. Since dozing never oc-
YOUNG, KATZ, AND WOODS
350S
TABLE I
Dose Schedule and Effects of Chronic Administration








1 1 0.17 5.0
4 2 0.3 6.0
6 2 0.56 4.0
9 2 1.0 4.0
10 1 1.7 4.0
15 2 3.0 0
17 3 5.6 1.0
19 3 10.0 0
* Injections occurred every 6 hours starting at 7A.M.; the I A.M. injection the following
morning was considered the fourth of the day.
** Scoring of cannabinoid effects is described in the methods section; scores ranged
from zero (no effect) to 10 (full effects). These scores are initial effects of the drug at 1
hour after administration.
curved throughout grading periods, it was
always possible to grade each effect. Thus,
each monkey received a score ranging from
zero, representing no effect, to 10, repre-
senting full effects.
Acute effects of levonantradol were de-
termined with doses given no more fre-
quently than once per 72 hours. High and
low doses alternated so that two high doses
were not administered in close succession.
The doses studied were 0.03, 0.1, 0.17, and
0.3 mg/kg. Additionally, effects of 0.3
mg/kg were studied in combination with
3.0 mg/kg naloxone. Selected doses of
other compounds were studied in order to
later estimate whether tolerance to effects
of levonantradol conferred cross tolerance
to effects of these compounds. The drugs
and doses tested were 3.0 mg/kg THC, 0.56
mg/kg nabilone, 0.1 mg/kg UM 1072 (a
narcotic agonist of the kappa type), and 3.0
mg/kg morphine. Following the determi-
nation of acute effects, injections of levo-
nantradol were administered every 6 hours,
starting at a dose of 0.17 mg/kg and in-
creasing dosage whenever there was clear
tolerance to the observable effects of the
drug. The exact schedule of dose incre-
ments is provided in Table I. On the 14th,
15th, and 16th days of chronic administra-
tion, the monkeys were also injected with
nalorphine, saline, and naloxone, respec-
tively, and observed for any morphine-like
withdrawal effects. The test with naloxone
was repeated on the 21st day. Following
four days of stabilization on 10.0 mg/kg
levonantradol every 6 hours, effects of still
higher doses (30.0 and 100.0 mg/kg) of le-
vonantradol and of selected doses of addi-
tional compounds were assessed when ad-
ministered in lieu of the second (1 P.M.)
injection of the day. During these tests rou-
tine injections at the other times of the day
continued. After the third injection on the
31st day of chronic levonantradol adminis-
tration, all further injections were sus-
pended, and the monkeys were observed for
any signs of withdrawal.
Intravenous Drug Self-
Administ ration Studies
Rhesus monkeys were conditioned to self-
administer codeine, and the ability of nan-
tradol and levonantradol to maintain be-
havior was evaluated under a substitu-
tional Monkeys were housed in
fiber glass cubicles and fed approximately
150 Gm Purina Monkey Chow daily. Water
was available at all times. Each monkey
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received an isoniazid sugar cube (40
mg/cube) daily and fresh fruit several
times per week.
Each monkey was prepared with a
chronic indwelling siliconized rubber cath-
eter implanted in a jugular, femoral, or
brachial vein. To protect the catheter, the
monkey wore a stainless steel harness
that was connected by a jointed arm to the
back of the experimental cubicle. The cath-
eter passed through the arm to an infusion
pump, which delivered 1 ml over 5 seconds.
Mounted on the front panel of the cubicle
were one green and two red stimulus lights
and two response keys. Experimental con-
ditions and data collection were arranged
by a digital computer located in an adjacent
room.
Drug injections were available during
each of two daily 130-minute experimental
sessions, which were separated by at least 4
hours. During each session, responses on
the right lever were maintained under a
fixed-ratio (FR) 30, timeout 600-second
schedule of intravenous injection of codeine
(0.32 mg/kg per injection). When the right
green stimulus light was illuminated, 30
presses on the right lever (fixed-ratio, or FR,
30 schedule) produced a 5-second codeine
infusion, during which the right stimulus
light was out and the middle light was il-
luminated red. The infusion was followed
by a 600-second timeout period, during
which all stimulus lights were out and re-
sponses had no scheduled consequences. At
the end of 600 seconds the right stimulus
light was again illuminated, and the entire
cycle was repeated. Each session termi-
nated after 13 infusions or 130 minutes,
whichever occurred first. During selected
sessions the maintenance dose of codeine
was replaced with saline, cannabinoid ve-
hicle, or selected doses of the cannabinoids.
Nantradol hydrochloride was substituted
ininjectiondosesofO.001 to0.1 mg/kg(2.11
X10 to 2.11 X i07 mole/kg); levonan-
tradol hydrochloride was substituted in in-
jection doses of 0.001 to 0.032 mg/kg (2.11 X
10 to 6.33 to 10 mole/kg). Two observa-
tions of each dose were made in each of
three monkeys. FR response rate (the rate
of right lever presses during the FR corn po-
nent divided by the time elapsed from the
onset of the FR component until solution
delivery) and the number of infusions deliv-
ered were recorded for each experimental
session.
Discriminative Effects of Levonantradol
The discriminative stimulus properties of
levonantradol were compared to those of
ethylketazocine and etorphine in the mon-
key. Rhesus monkeys were reduced to ap-
proximately 85 per cent of their ad libitum
feeding weights (7.5 to 9.0 kg) and provided
with sufficient Purina Monkey Chow after
each session to maintain these weights. All
monkeys were housed individually, with
water freely available. For experimental
testing, the monkeys were transported from
their individual home cages and restrained
in the experimental chambers by primate
chairs. The experimental chambers were
equipped with two response levers mounted
equidistant from a central food receptacle.
An exhaust fan was used for ventilation;
white noise was provided by a speaker in
the chamber to mask extraneous noises.
The intramuscular injection of ethylke-
tazocine or etorphine was established as a
discriminative stimulus for the food-re-
inforced responses of rhesus monkeys.”
Responses on the right or left response lever
were reinforced by the delivery of a 300-mg
banana-flavored food pellet depending on
whether drug or saline had been injected
intramuscularly. The training dose of
ethylketazocine (0.01 mg/kg) was adminis-
tered 10 minutes before the session; the
training dose of etorphine (0.00032 mg/kg)
was administered 20 minutes before the
session. Twenty consecutive responses on
the appropriate lever were required for food
delivery (FR 20 schedule); responses on the
inappropriate lever reset the FR require-
ment for responses on the appropriate
lever. Sessions ended after the delivery of
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75 food pellets or 1 hour, whichever oc-
curred first. During training, saline and
drug administrations alternated daily.
Discriminative control met criterion if the
subject (1) emitted less than 40 responses
before the first food delivery and (2) distrib-
uted at least 90 per cent of the total session
responses on the appropriate lever.
The ability of levonantradol to occasion
drug-appropriate responding was deter-
mined during test sessions. During the test
sessions, 20 consecutive responses on either
the drug- or saline-appropriate lever were
reinforced throughout the session, and the
pretreatment time was extended to 30 min-
utes. Training days alternated with test
days to ensure that discriminative respond-
ing was maintained. Whenever a monkey
failed to achieve the discrimination criteria
on a training day, further testing was post-
poned until these criteria were met on at
least two consecutive days. A complete dose-
response function for levonantradol was
obtained in two or three subjects to estab-
lish the extent to which it produced discrim-
inative effects similar to those of the train-
ing drug. Dose-effect evaluations
were conducted until either levonantradol
produced an equivalent response to the
training drug (e.g., over 90 per cent drug-
appropriate responding) or until doses were
reached that markedly reduced the rate of
responding during the test session. The
order of doses tested in each subject was
mixed. The number of responses on the
drug-appropriate lever was expressed as a
percentage of the total responses on both
levers during the session, and the rate of
responses on either lever during the entire
session was expressed as a percentage of
the rate of responding on saline training
days.
Drugs
Codeine phosphate, morphine sulfate,
UM 1072 [(±)-(1R/S,SR/S,9R/S,2”R/S)-5,9-
a-dimethyl-2’-hydroxy-2-tetrahydrofurfuryl-6,
7-benzomorphan hydrochloride] and nal-
oxone hydrochloride were dissolved in ster-
ile isotonic saline. Nalorphine hydrochlo-
ride was dissolved in distilled water. Nan-
tradol hydrochloride, levonantradol hydro-
chloride, and THC were suspended in a
mixture of Emulphor, ethanol (95 per cent),
and saline. Nabilone was suspended in a
mixture of Tween 80, ethanol (95 per cent),
and water. For intravenous injection, solu-
tions of cannabinoids were prepared in a
concentration of 1.0 mg/ml; lower concen-
trations were prepared by dilution with ster-
ile saline. For intramuscular and subcu-
taneous injection, concentrations were
prepared to deliver all doses in volumes no
greater than 2 ml/kg. Doses of THC and
nabilone are expressed as the base; doses of
other compounds are expressed as the salt.
Results
Dependence and Tolerance Studies
Suppression of Morphine Withdrawal.
Neither nantradol (0.2 to 0.4 mg/kg) nor
levonantradol (0.032 to 0.56 mg/kg) com-
pletely suppressed morphine withdrawal
signs in the rhesus monkey (Table II). In-
terestingly, both compounds at suitable
doses (levonantradol: 0.1 to 0.56 mg/kg;
nantradol: 0.2 mg/kg) produced a relaxa-
tion of the abdominal musculature that is
typically contracted during morphine
withdrawal. At the highest dose of levo-
nantradol tested (0.56 mg/kg), the abdomi-
nal relaxation was accompanied by a de-
crease in the responsivity of the subject to
abdominal pressure that accompanies the
contraction seen during withdrawal. Other
signs of withdrawal, including restless-
ness, retching and vomiting, lying on the
side, and skeletal muscle rigidity, were not
alleviated by either compound. In sum,
neither levonantradol nor nantradol pro-
duced a marked change in the normal pro-
gression of the withdrawal syndrome from
morphine in the monkey as indicated by the
overall withdrawal scores (Table II). In
contrast, 3.0 mg/kg morphine sulfate
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TABLE II
Effects of Levonantradol, Nantradol, Morphine, and
Vehicle Injections on Morphine























































- 3.7 42 4.5 4.7
* Scores range from zero (no withdrawal signs) to 8 (severe withdrawal). Scoring of
withdrawal is according to the scale developed by Deneau and Seeversn and described
by Villarreal.n Average scores are based on single observations in three to four
monkeys.
quickly produced complete or near-com-
plete suppression of withdrawal.
Acute and Chronic Effect8 in Normal
Monkeys. The acute effects of both nan-
tradol and levonantradol were character-
ized by five major effects: pupil dilation,
ataxia with body sag, ptosis, dozing, and
reduced reactivity to external stimuli, in-
cluding those from cagemates and human
observers. There was also a decrease in lo-
comotor activity possibly due to the ataxia,
assumption of peculiar postures, and some-
times vacant staring. None of these effects
was reversed by subcutaneous injection of
1.7 mg/kg naloxone, a dose that is capable
of completely reversing opiate agonist ef-
fects (e.g., 5 mg/kg morphine).
Grades consisting of scores of the five
major grossly observable effects of levo-
nantradol, as described above, are shown
as a function of dose in Figure 1. From the
dose-effect function, the estimated dose of
levonantradol to produce 50 per cent of the
maximum effects was 0.13 mg/kg. Nan-
tradol was tested at a single dose (0.4
mg/kg), which produced full effects in all
subjects (a score of 10). As with levonan-
tradol, effects of nantradol were not af-
fected by naloxone. Doses ofTHC and nabi-
lone produced similar effects, scores of
which are given in Table III (“before” col-
umn). Effects of both UM 1072 and mor-
phine are also shown. While UM 1072 pro-
duced some effects resembling those of the
cannabinoids (e.g., pupil dilation), the ef-
fects of morphine were generally different,
accounting for the low score at a behavior-
ally active dose. With 3.0 mg/kg morphine,
there was little ataxia and dozing, only
slight decreases in responsivity to external
stimuli, and no ptosis. Additionally, there













Effects of Levonantradol, THC,
Nabilone, UM 1072, and Morphine on
Grossly Observable Behavior in
- Rhesus Monkeys Before and During
0.1 0.17 0.3 Repeated Levonantradol Administration5
* Scoring of grossly observable effects is described in
the methods section; scores ranged from zero (no effect)
to 10 (full effect) Scores in the column labeled “before”
represent the mean of observations in at least two, and
typically three, animals before the initiation of repeated
levonantradol injections. Scores in the column labeled
“during” represent the mean of observations in at least
three animals during repeated levonantradol injections.
Scores in the column labelled “during” at doses up to 10
mg/kg levonantradol are the final scores for that dose
during the repeated injection regimen; scores for levo-
nantradol doses greater than 10 mg/kg and for THC,
nabione, UM 1072, and morphine are for single obser-
vations in each of three monkeys during repeated injec-
tions of 10 mg/kg levonantradol.




Fig. 1.Effects of levonantradol on grossly observ-
able effects in rhesus monkeys. Scores were as-
signed according to the scale described in the
text. Each point is typically the mean of one ob-
servation at each dose in each of three monkeys.
See text for further details.
Table I shows the schedule of dose incre-
ments over the course of chronic levonan-
tradol administration; dose increments
were made in one-quarter log units when
complete or near complete (score between 0
and 1) tolerance developed to the effects of
the lower dose. As can be seen in Table I, the
first four-dose increments produced effects
approximating those seen initially. Follow-
ing the development of tolerance at 1.7
mg/kg per injection, however, it was not
possible to recapture the initial effects of
levonantradol with further dose incre-
ments. At the highest dose that was admin-
istered every 6 hours (10.0 mg/kg), there
was virtually complete tolerance to all of
the effects seen during acute administra-
tion of levonantradol (Table HI, column la-
beled “during”). Substitutions of still
higher doses (30.0 and 100.0 mg/kg) also
did not produce any substantial effects, in-
dicating a pronounced tolerance to the ef-
fects of levonantradol. Additionally, there
was cross tolerance to the effects of THC
and nabilone (Table III). Doses of these
cannabinoids that earlier had produced
nearly full effects on the scale no longer
produced any effects.
In contrast to the pronounced tolerance
to effects of the cannabinoids, there was
relatively little if any cross tolerance to ef-
fects of the narcotics UM 1072 and mor-
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Fig. 2. Rates of re8ponding maintained undera FR 30-second, TO &i0-second
schedule of intravenous drug injections under various conditions. The
available injection was either 0.32 mg/kg codeine (COD), saline (SAL),
vehicle (VEH: Emulphor, 95% ethanol, and sterile water), or doses of levo-
nantradol or nantradol. Doses of levonantradol and nantradol were substi-
tuted twice in each of three monkeys identified by the numbers and symbols
in the upper right corners. The nantradol and levonantradol injection doses
were 0.001, 0.003, 0.01, and 0.03 mg/kg and, for nantradol, 0.1 mg/kg. For
each figure, the average (closed circles) represents the mean rate during two
codeine baseline sessions or substitution test sessions for the three m.on-
keys. Grand average (open circle) is a historical control value for responding
of 20 monkeys under the 0.32 mg/kg codeine and saline conditions. Dashed
lines give ± 3 S.E.M. for the codeine average and +3 S.E.M. for the saline
average.
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S.E V 000I 00032 001 0032 0 I 0 32
mg/kg
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mg/kg
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Fig. 3. Discriminative stimulus and rate-decrea8ing effects of levonantradol in rhesus monkeys.
Etorphine (0.00032 mg/kg) or ethylketazocine (0.01 mg/kg) was established as a discriminative
stimulus for food-maintained behavior in different groups of monkeys. Upper panel ordinates:
Number of responses on the training drug-appropriate lever, expressed as percentage of the total
session responses. Lower panel ordinates: Rate of responding, expressed as percentage of the re-
sponse rate during saline training sessions. Abscissae: Dosesof levonantradol. Response distribution
and rates following levonantradol vehicle are presented at V;performance during training 8essions is
presented at S,E (upper panels) and E (lower panels). Each levonantradol and vehicle data point
represents a single determination in one monkey; each monkey is represented by a different symbol.
The starred open square in the right panel represents a second determination in monkey 950 at 0.1
mg/kg.
phine. With UM 1072 there appeared to be a
dampened response to 0.1 mg/kg; however,
0.3 mg/kg produced effects comparable to
those obtained earlier at the lower dose.
Additionally, the effects of 3.0 mg/kg mor-
phine, which were slight to begin with, were
modified only to a small degree by the pro-
found tolerance that developed to levonan-
tradol (Table III). Moreover, other effects of
morphine (e.g., scratching and rubbing the
eyes) were still quite apparent in the ani-
mals tolerant to levonantradol.
Neither administration of the narcotic
antagonists nalorphine (day 14) and nal-
oxone (days 16 and 21) nor abrupt discon-
tinuation of levonantradol injections (day
31) produced any clear signs of withdrawal.
There was some irritability to handling af-
ter the discontinuance of levonantradol in-
jections and a slight delay to eat food at the
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once-daily feedings. Normal monkeys typi-
cally begin eating at once when the food is
given. The increases in latency to eat were




Nantradol and levonantradol did not
maintain responding by rhesus monkeys
experienced in self-administering codeine
(Fig. 2). Over a 32- to 100-fold range ofinjec-
tion doses, nantradol and levonantradol
maintained response rates and injection
frequencies no higher than those main-
tained by either saline or the cannabinoid
vehicle. Following injection of the highest
tested doses of nantradol (0.1 mg/kg) and
levonantradol (0.032 mg/kg), the monkeys
were occasionally observed on closed-
circuit TV to sit with their eyes closed and
head dropped; no gross motor incoordina-
tion was observed. The monkeys continued
to respond at usual rates for codeine injec-
tions during the intervening experimental
sessions.
Discriminative Effects of Levonantradol
When the administration of narcotics
served as discriminative stimuli for food-
reinforced responding, levonantradol pro-
duced equivocal results (Fig. 3). In monkeys
for which ethylketazocine served as a dis-
criminative stimulus, one dose of levonan-
tradol, 0.1 mg/kg, occasioned drug-ap-
propriate responding in one of three
monkeys. At lower doses, levonantradol oc-
casioned intermediate responding in this
monkey. In the two other monkeys for
which ethylketazocine served as a discrim-
inative stimulus, levonantradol did not oc-
casion ethylketazocine-appropriate re-
sponding at any dose, including doses that
decreased rates of responding. In the mon-
keys for which etorphine served as a dis-
criminative stimulus for food-maintained
responses, levonantradol occasioned drug-
appropriate responding at one dose. Lower
and higher doses produced only saline-
appropriate responding,
Discussion
A number of recent studies have sug-
gested that cannabinoids may be effective
in alleviating opiate withdrawal signs in a
variety of nonprimate species (see Sie-
mens26 for a review, and papers by Gilbert
and Lal et al. in this issue). In most previous
studies, doses of THC that suppressed
withdrawal signs were of a magnitude that
produce general depressant effects that
may have made the observation of with-
drawal signs difficult.27 In a well-consid-
ered set of experiments, Frederickson et
al.28 studied naloxone-precipitated with-
drawal in guinea pigs and rats. Effects of
THC on the withdrawal signs of guinea
pigs were greater than those for rats. Addi-
tionally, the effects were stereospecific; the
synthetic (+)-isomer was essentially inac-
tive. Finally, in guinea pigs there was a
clear separation of the effects of THC on
withdrawal scores and the general depres-
sant effects of the drug that was not seen
with pentobarbitol. In contrast, the present
experiments failed to find any effect of the
cannabinoid levonantradol on most mor-
phine withdrawal signs in the monkey, al-
though an interesting selective alleviation
of abdominal signs was observed. This se-
lective effect on the abdominal musculature
deserves further study. It appears, how-
ever, that whether or not cannabinoids se-
lectively affect opiate withdrawal is largely
dependent on the species studied.
The present findings of profound toler-
ance to effects of levonantradol are consis-
tent with studies of tolerance to the effects of
cannabinoids in both laboratory animals’9
and humans. Additionally, tolerance to
effects of levonantradol conferred cross tol-
erance to the effects of other cannabinoids,
but only limited, if any, cross tolerance to
the effects of opiates. Similar cross toler-
ance among cannabinoids but not opiates
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has been described in pigeons.’9’3#{176} Other
workers2”3’ have described tolerance and
dependence development with chronic ad-
ministration of THC, while only tolerance
to levonantradol was observed in the pres-
ent study. Signs of cannabinoid abstinence
described in those studies, such as tremors
occasionally involving the whole body, hy-
perirritablilty, yawning, and penile erection,
were either not seen or not seen with any
frequency indicative of a definite with-
drawal syndrome. Current studies are
under way in order to determine whether with-
drawal effects can be obtained in monkeys
rendered tolerant to THC.
Levonantradol and racemic nantradol did
not maintain responses leading to their in-
travenous injection in rhesus monkeys ex-
perienced in self-administering codeine.
These results are consistent with previous
reports’6”7 that other cannabinoids, includ-
ing THC, also do not serve as intravenous
reinforcers under conditions sufficient to
demonstrate the reinforcing properties of
narcotics and central nervous system
stimulants.
Levonantradol did not unequivocally
share discriminative stimulus properties
with the narcotics etorphine or ethylketaz-
ocine in the monkey. Response generaliza-
tion to ethylketazocine occurred in only one
of three monkeys, and response generaliza-
tion to etorphine occurred only at interme-
diate doses of levonantradol. These pat-
terns of discriminative effect are not char-
acteristic of compounds that share dis-
criminative and other pharmacologic ef-
fects with either ethylketazocine or etor-
phine in the monkey.’#{176}”1 Differences among
subjects and a lack of dose dependence in
the present study render interpretations of
the results difficult. Other investigators’2
have reported that THC does not share dis-
criminative stimulus effects with the nar-
cotic morphine in the rat and pigeon. In
general, cannabinoids have been found to
produce unique discriminative effects
which are shared by other cannabinoids
358S
but not by members of other pharmacologic
classes.’2”3
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